Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 45Carcinoma, Non-Small-Cell Lung 2Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrence 1Pleuropulmonary blastoma 1Patient Preference 1Pancreatic Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasm Metastasis 1Multiple Myeloma 1Inflammatory Breast Neoplasms 1HER2 Positive Breast Cancer 1Genomic Instability 1Cholangiocarcinoma 1Breast Cancer Metastatic 1Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

lorvotuzumab mertansine 1Polymerase Chain Reaction 1Gene Rearrangement 1Gene Expression Profiling 1Cytogenetic Analysis 1Amplified Fragment Length Polymorphism Analysis 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pleuropulmonary blastoma × Ado-Trastuzumab Emtansine × Clear all
NCT02452554 2022-01-13

Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

Children's Oncology Group

Phase 2 Completed
62 enrolled 15 charts
CNSGenitourinarySarcoma

Pleuropulmonary blastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Synovial, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡